When I last covered Madrigal Pharmaceuticals (NASDAQ: MDGL ) in April 2024, I predicted a strong launch for Rezdiffra (resmetirom) in metabolic-associated steatohepatitis (MASH). The stock is up over 60% since that article with the first two quarters of Rezdiffra sales beating estimates. There haveScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, ...